Main Article Content

Asma Batool
Sara F. Ghanem
Hamza jan
Huda Ismail
Marzough Aziz Albalawi
Rehab Al-Massabi
Sanaa Almowallad
Amnah A. Alharbi
Mody Albalawi
Nahla Zidan


Peppermint oil, Mentha piperita L., menthol, liver function enzymes, oxidative stress, lipid peroxidation


The complexity, diagnosing challenges, and lack of recognized therapies for non-alcoholic fatty liver disease have made it a major problem. It is anticipated that non-alcoholic fatty liver disease (NAFLD) will surpass hepatitis C as the most prevalent chronic liver disease in adults and children over the next ten years. It is also anticipated to emerge as the primary reason for liver transplantation. It coexists with obesity, hypertension, type 2 diabetes mellitus, and dyslipidemia. Current clinical trials have concentrated on a number of disease reasons, and how these treatments fit into the current paradigm of substrate overload lipotoxic liver injury has been addressed here. Many of the approaches concentrate on downstream events such inflammation, damage, and fibro genesis. Many natural therapies are used to combat elevated liver function enzymes and lipid peroxidation in patients of NAFLD.  Mentha piperita L. and M. arvensis var. piperascens, two perennial plants in the Labiatae family, are used to extract peppermint oil from their leaves. Popular and significant, this plant is used extensively for a variety of therapeutic purposes in many indigenous medical systems. These include analgesic, anaesthetic, antiseptic, astringent, carminative, decongestant, expectorant, nervine, stimulant, stomachic, inflammatory diseases, ulcer, and stomach issues. The present study was to highlight the therapeutic effect of peppermint oil against elevated liver enzymes alanine transaminase (ALT) aspartate transaminase,(AST) and melanodialdehyde(MDA).For this purpose the paper mint oil was firstly observed for its chemical composition  afterwards  Thirty (30)male albino rats were induced with induced fatty liver disease by induction of  using the mixture of  high fat and high fructose diet and divide them in equal quantity in equal groups in which control group was G0 was observed as control group was not received and G1 and G2 were observed as treatment group and they were given 30ml and 60 ml of peppermint oil as per kg of their body weight. After that liver enzymes ALT, AST AND MD were measured before and after the trial using ANOVA test. Both treatment groups showed significant reduction in elevated liver enzymes alanine transaminase, and aspartate transaminase. A significant reduction was also seen in lipid peroxidation parameter melanodialdehyde in treatment groups. All results were taken significant art p<0.05.

Abstract 941 | PDF Downloads 225


1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease— meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
2. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20
3. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 739–52
4. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–402.
5. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 2019; 92: 82–97.]
6. Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015; 110: 1306–14
7. Ballestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D., & Lonardo, A. (2017). NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Advances in therapy, 34, 1291-1326.
8. Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24(11):835–8. [PubMed] [Google Scholar]
9. Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5’-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology. 1984;86(4):632–6. [PubMed] [Google Scholar]
10. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–7. [PubMed] [Google Scholar]
11. Murag, S., Ahmed, A., & Kim, D. (2021). Recent epidemiology of nonalcoholic fatty liver disease. Gut and liver, 15(2), 206.
12. Reddy, L. A. L. I. N. I., Odhav, B., & Bhoola, K. D. (2003). Natural products for cancer prevention: a global perspective. Pharmacology & therapeutics, 99(1), 1-13.
13. Çoban, Ö., & Baydar, N. G. (2016). Brassinosteroid effects on some physical and biochemical properties and secondary metabolite accumulation in peppermint (Mentha piperita L.) under salt stress. Industrial Crops and Products, 86, 251-258.
14. Adams, R. P. (2001). Identification of essential oil components by gas chromatography/quadrupole mass spectroscopy. Allured publishing corporation.
15. Paduraru, I., Saramet, A., Danila, G. H., Nichifor, M., Jerca, L., Iacobovici, A., ... & Filip, M. (1996). Antioxidant action of a new flavonic derivative in acute carbon tetrachloride intoxication. European journal of drug metabolism and pharmacokinetics, 21, 1-6.
16. Barrière, D. A., Noll, C., Roussy, G., Lizotte, F., Kessai, A., Kirby, K., ... & Sarret, P. (2018). Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. Scientific Reports, 8(1), 424.
17. Bhide, A., Shah, P. S., & Acharya, G. (2018). A simplified guide to randomized controlled trials. Acta obstetricia et gynecologica Scandinavica, 97(4), 380-387.
18. Marjani, A., Rahmati, R., Mansourian, A. R., & Veghary, G. (2012). Effect of Peppermint Oil on Serum Lipid Peroxidation and Hepatic Enzymes after Immobility Stress in Mice. The O. Biochem. J., 6, 51–55.
19. Manivannan, R., & Shopna, R. (2017). Antidiabetic activity of Calotropis gigantea white flower extracts in alloxan induced diabetic rats. Journal of Drug Delivery and Therapeutics, 7(3), 106-111.
20. D’Agostino, R. B. (2017). Tests for the normal distribution. In Goodness-of-fit techniques (pp. 367–420). Routledge.
21. Marjani, A., Rahmati, R., Mansourian, A. R., & Veghary, G. (2012). Effect of Peppermint Oil on Serum Lipid Peroxidation and Hepatic Enzymes after Immobility Stress in Mice. The O. Biochem. J., 6, 51–55.
22. Mimica-Dukic N, Bozin B, Sokovic M, Mihajlovic B, Matavulj M. Antimicrobial and antioxidant activities of three Mentha species essential oils. Planta Med. 2003;69:413–419. [PubMed] [Google Scholar]
23. Thorup I, Wurtzen G, Carstensen J, Olsen P. Short term toxicity study in rats dosed with pulegone and menthol. Toxicol. Lett. 1983b;19:207–210. [PubMed] [Google Scholar]
24. Balamash, K., & Nour, N. (2019). Impact of Peppermint and Thyme in Ameliorating Cardiac and Hepatic Disorders Induced by Feeding Rats Repeatedly Heated Fried Oil. 6.
25. Al-Hamdany, M., Al-Tai, F., & Ismail, H. K. (2022). Histological changes induced by Piroxicam on the hepatic and renal tissues of mice with and without administration of Peppermint oil. Curr. Iss. in Phar. and Med. Sci.

Most read articles by the same author(s)